Merestinib dihydrochloride
Product Specifications
UNSPSC Description
Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].
Target Antigen
c-Met/HGFR; Discoidin Domain Receptor; FLT3; ROS Kinase
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY2801653-dihydrochloride.html
Solubility
DMSO : ≥ 100 mg/mL
Smiles
[H]Cl.[H]Cl.O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
Molecular Weight
625.45
References & Citations
[1]Yan SB, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.|[2]Barat S, et al. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016 Jan 12.Methods Mol Biol. 2018;1711:351-398.|bioRxiv. 2024 May 8:2024.05.07.592424.|Cancer Discov. 2016 Dec;6(12):1334-1341.|Clin Cancer Res. 2020 Jun 1;26(11):2615-2625.|Patent. WO2017019702A1.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-15514A/Merestinib-dihydrochloride-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-15514A/Merestinib-dihydrochloride-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1206801-37-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
